Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.

Onco Targets Ther · 2012 · PMC3346061 · PMID 22573938

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A favorable trend toward improvement in median progression-free survival (6.0 months versus 4.1 months) and overall survival (13.0 months versus 9.7 months) was also observed in the vorinostat arm.

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.